Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome
10.1038/sj.gt.3301865
Crossref journal-article
Springer Science and Business Media LLC
Gene Therapy (297)
Bibliography

Cordeiro, M. F., Mead, A., Ali, R. R., Alexander, R. A., Murray, S., Chen, C., York-Defalco, C., Dean, N. M., Schultz, G. S., & Khaw, P. T. (2003). Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome. Gene Therapy, 10(1), 59–71.

Authors 10
  1. M F Cordeiro (first)
  2. A Mead (additional)
  3. R R Ali (additional)
  4. R A Alexander (additional)
  5. S Murray (additional)
  6. C Chen (additional)
  7. C York-Defalco (additional)
  8. N M Dean (additional)
  9. G S Schultz (additional)
  10. P T Khaw (additional)
References 63 Referenced 130
  1. Thylefors B, Negrel A . The global impact of glaucoma. Bulletin World Health Org 1994; 72: 323–326. / Bulletin World Health Org by B Thylefors (1994)
  2. Foster A, Johnson GJ . Magnitude and causes of blindness in the developing world. Int Ophthalmol 1990; 14: 135–140. (10.1007/BF00158310) / Int Ophthalmol by A Foster (1990)
  3. Quigley HA . Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389–393. (10.1136/bjo.80.5.389) / Br J Ophthalmol by HA Quigley (1996)
  4. Sommer A . Glaucoma: facts and figures (Doyne lecture). Eye 1996; 10: 295–301. (10.1038/eye.1996.63) / Eye by A Sommer (1996)
  5. Jay JL . Rational choice of therapy in primary open angle glaucoma. Eye 1992; 6: 243–247. (10.1038/eye.1992.47) / Eye by JL Jay (1992)
  6. Migdal C, Gregory W, Hitchings RA . Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994; 101: 1651–1656. (10.1016/S0161-6420(94)31120-1) / Ophthalmology by C Migdal (1994)
  7. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 490–491. (10.1016/S0002-9394(00)00538-9)
  8. Addicks EM, Quigley HA, Green WR, Robin AL . Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983; 101: 795–798. (10.1001/archopht.1983.01040010795021) / Arch Ophthalmol by EM Addicks (1983)
  9. Hitchings RA, Grierson I . Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983; 103: 84–88. / Trans Ophthalmol Soc UK by Hitchings RA (1983)
  10. Stamper RL, McMenemy MG, Lieberman MF . Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992; 114: 544–553. (10.1016/S0002-9394(14)74481-2) / Am J Ophthalmol by RL Stamper (1992)
  11. Parrish R, Minckler D . Late endophthalmitis – filtering surgery time bomb? Ophthalmology 1996; 103: 1167–1168. (10.1016/S0161-6420(96)30527-7) / Ophthalmology by R Parrish (1996)
  12. Jampel HD, Pasquale LR, Dibernardo C . Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol 1992; 110: 1049–1150. (10.1001/archopht.1992.01080200029011) / Arch Ophthalmol by HD Jampel (1992)
  13. Ashcroft GS et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997; 3: 1209–1215. (10.1038/nm1197-1209) / Nat Med by GS Ashcroft (1997)
  14. Shah M, Foreman DM, Ferguson MW . Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108: 985–1002. (10.1242/jcs.108.3.985) / J Cell Sci by M Shah (1995)
  15. Levine JH, Moses HL, Gold LI, Nanney LB . Spatial and temporal patterns of immunoreactive transforming growth factor-beta-1, -beta-2 and -beta-3 during excisional wound repair. Am J Pathol 1993; 143: 368–380. / Am J Pathol by JH Levine (1993)
  16. Merwin JR et al. Vascular cell responses to TGF-β3 mimic those of TGF-β1 in vitro. Growth Factors 1991; 5: 149–158. (10.3109/08977199109000279) / Growth Factors by JR Merwin (1991)
  17. Lutty GA et al. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous and choroid. Invest Ophthalmol Vis Sci 1993; 34: 477–487. / Invest Ophthalmol Vis Sci by GA Lutty (1993)
  18. Pasquale LR et al. Immunolocalisation of TGF-beta1, TGF-beta2 and TGF-beta3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 1993; 34: 23–30. / Invest Ophthalmol Vis Sci by LR Pasquale (1993)
  19. Imanishi J et al. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000; 19: 113–129. (10.1016/S1350-9462(99)00007-5) / Prog Retin Eye Res by J Imanishi (2000)
  20. Connor TB et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 1989; 83: 1661–1666. (10.1172/JCI114065) / J Clin Invest by TB Connor (1989)
  21. Kon CH, Occleston NL, Aylward GW, Khaw PT . Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999; 40: 705–712. / Invest Ophthalmol Vis Sci by CH Kon (1999)
  22. Carrington L, McLeod D, Boulton M . IL-10 and antibodies to TGF-beta2 and PDGF inhibit RPE-mediated retinal contraction. Invest Ophthalmol Vis Sci 2000; 41: 1210–1216. / Invest Ophthalmol Vis Sci by L Carrington (2000)
  23. Lee EH et al. Overexpression of the transforming growth factor-beta-inducible gene betaig-h3 in anterior polar cataracts. Invest Ophthalmol Vis Sci 2000; 41: 1840–1805. / Invest Ophthalmol Vis Sci by EH Lee (2000)
  24. Nishi O, Nishi K, Wada K, Ohmoto Y . Expression of transforming growth factor (TGF)-alpha, TGF-beta(2) and interleukin 8 messenger RNA in postsurgical and cultured lens epithelial cells obtained from patients with senile cataracts. Graefes Arch Clin Exp Ophthalmol 1999; 237: 806–811. (10.1007/s004170050316) / Graefes Arch Clin Exp Ophthalmol by O Nishi (1999)
  25. Saika S et al. Immunolocalization of TGF-beta1, -beta2, and -beta3, and TGF-beta receptors in human lens capsules with lens implants. Graefes Arch Clin Exp Ophthalmol 2000; 238: 283–293. (10.1007/s004170050354) / Graefes Arch Clin Exp Ophthalmol by S Saika (2000)
  26. Cordeiro MF, Gay JA, Khaw PT . Human anti-TGF-β2 monoclonal antibody: a new anti-scarring agent for glaucoma filtration surgery. Invest Ophthalmol Vis Sci 1999; 40: 2225–2234. / Invest Ophthalmol Vis Sci by MF Cordeiro (1999)
  27. Cordeiro MF et al. TGF-β1, -β2 & -β3 in vivo: effects on normal and Mitomycin-C modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999; 40: 1975–1982. / Invest Ophthalmol Vis Sci by MF Cordeiro (1999)
  28. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT . TGF-β1, -β2 & -β3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation & migration. Invest Ophthalmol Vis Sci 2000; 41: 756–763. / Invest Ophthalmol Vis Sci by MF Cordeiro (2000)
  29. Siriwardena D et al. Human anti-transforming growth factor beta-2 monoclonal antibody – a new modulator of wound healing in trabeculectomy: a randomised placebo controlled clinical study. Ophthalmology 2002; 109: 427–431. (10.1016/S0161-6420(01)00997-6) / Ophthalmology by D Siriwardena (2002)
  30. Tamm I, Dorken B, Hartmann G . Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489–497. (10.1016/S0140-6736(01)05629-X) / Lancet by I Tamm (2001)
  31. Orr RM . Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 2001; 3: 288–294. / Curr Opin Mol Ther by RM Orr (2001)
  32. Lang KA, Peppercorn MA . Promising new agents for the treatment of inflammatory bowel disorders. Drugs R D 1999; 1: 237–244. (10.2165/00126839-199901030-00011) / Drugs R D by KA Lang (1999)
  33. Yacyshyn BR et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133–1142. (10.1016/S0016-5085(98)70418-4) / Gastroenterology by BR Yacyshyn (1998)
  34. Crooke ST . Basic principles of antisense technology. In: Crooke ST (ed). Antisense Drug Technology: Principles, Strategies and Applications. Marcel Dekker: New York, 2001, pp 1–28. (10.1201/9781420002546) / Antisense Drug Technology: Principles, Strategies and Applications by ST Crooke (2001)
  35. Stephenson ML, Zamecnik PC . Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978; 75: 285–288. (10.1073/pnas.75.1.285) / Proc Natl Acad Sci USA by ML Stephenson (1978)
  36. Dean NM, Butler M, Monia BP, Manoharan M . Pharmacology of 2′-O-(2-methoxy) ethyl-modified antisense oligonucleotides. In: Crooke ST (ed). Antisense Drug Technology: Principles, Strategies and Applications. Marcel Dekker: New York, 2001, pp 319–338. / Antisense Drug Technology: Principles, Strategies and Applications by NM Dean (2001)
  37. Dean NM, Griffey RH . Identification and charecterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Develop 1997; 7: 229–233. (10.1089/oli.1.1997.7.229) / Antisense Nucleic Acid Drug Develop by NM Dean (1997)
  38. Reichel MB et al. New model of conjunctival scarring in the mouse eye. Br J Ophthalmol 1998; 82: 1072–1077. (10.1136/bjo.82.9.1072) / Br J Ophthalmol by MB Reichel (1998)
  39. Cordeiro MF et al. Role of TGF-β in conjunctival scarring. Clin Sci 2002 (in press).
  40. Cordeiro MF et al. The effect of varying mitomycin-c treatment area in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 1997; 38: 1639–1646. / Invest Ophthalmol Vis Sci by MF Cordeiro (1997)
  41. Reichel ML et al. A new model of conjunctival scarring in the mouse eye. Invest Ophthalm Vis Sci 1996; 37: 91. / Invest Ophthalm Vis Sci by ML Reichel (1996)
  42. Flanders KC, Holder MG, Winokur TS . Autoinduction of mRNA and protein expression for transforming growth factor-beta S in cultured cardiac cells. J Mol Cell Cardiol 1995; 27: 805–812. (10.1016/0022-2828(95)90087-X) / J Mol Cell Cardiol by KC Flanders (1995)
  43. Cordeiro MF . Beyond Mitomycin – TGF-β and wound healing. Prog Ret Eye Res 2002; 21: 75–89. (10.1016/S1350-9462(01)00021-0) / Prog Ret Eye Res by MF Cordeiro (2002)
  44. Jampel HD, Roche N, Stark WJ, Roberts AB . Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990; 9: 963–969. (10.3109/02713689009069932) / Curr Eye Res by HD Jampel (1990)
  45. Tripathi RC, Li J, Chan WF, Tripathi BJ . Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 1994; 59: 723–727. (10.1006/exer.1994.1158) / Exp Eye Res by RC Tripathi (1994)
  46. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E . Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol 2001; 239: 199–207. (10.1007/s004170000252) / Graefes Arch Clin Exp Ophthalmol by G Picht (2001)
  47. Knisely TL, Bleicher PA, Vibbard CA, Granstein RD . Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr Eye Res 1991; 10: 761–771. (10.3109/02713689109013870) / Curr Eye Res by TL Knisely (1991)
  48. Tripathi RC, Chan WF, Li J, Tripathi BJ . Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res 1994; 58: 523–538. (10.1006/exer.1994.1046) / Exp Eye Res by RC Tripathi (1994)
  49. Massague J, Chen YG . Controlling TGF-beta signaling. Genes Dev 2000; 14: 627–644. (10.1101/gad.14.6.627) / Genes Dev by J Massague (2000)
  50. Lee SB et al. Suppression of TGF-beta signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. Curr Eye Res 2000; 20: 325–334. (10.1076/0271-3683(200004)2041-5FT325) / Curr Eye Res by SB Lee (2000)
  51. Obata H, Kaburaki T, Kato M, Yamashita H . Expression of TGF-beta type I and type II receptors in rat eyes. Curr Eye Res 1996; 15: 335–340. (10.3109/02713689609007629) / Curr Eye Res by H Obata (1996)
  52. Wrana JL et al. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370: 341–347. (10.1038/370341a0) / Nature by JL Wrana (1994)
  53. Nakao A et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16: 5353–5362. (10.1093/emboj/16.17.5353) / EMBO J by A Nakao (1997)
  54. Piek E, Heldin CH, Ten Dijke P . Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999; 13: 2105–2124. (10.1096/fasebj.13.15.2105) / FASEB J by E Piek (1999)
  55. Rotzer D et al. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J 2001; 20: 480–490. (10.1093/emboj/20.3.480) / EMBO J by D Rotzer (2001)
  56. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol 1989; 108: 625–635. (10.1016/0002-9394(89)90853-2)
  57. Kitazawa Y, Kawase K, Matsushita H, Minobe M . Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol 1991; 109: 1693–1698. (10.1001/archopht.1991.01080120077030) / Arch Ophthalmol by Y Kitazawa (1991)
  58. Katz GJ et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 1995; 102: 1263–1269. (10.1016/S0161-6420(95)30875-5) / Ophthalmology by GJ Katz (1995)
  59. Lamping KA, Belkin JK . F5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 1995; 102: 70–75. (10.1016/S0161-6420(95)31051-2) / Ophthalmology by KA Lamping (1995)
  60. Belyea DA et al. Late onset of sequential multifocal bleb leaks after glaucoma filtration surgery with 5-fluorauracil and mitomycin-C. Am J Ophthalmol 1997; 124: 40–45. (10.1016/S0002-9394(14)71642-3) / Am J Ophthalmol by DA Belyea (1997)
  61. Greenfield DS, Liebmann JM, Jee J, Ritch R . Late-onset bleb leaks after glaucoma filtering surgery. Arch Ophthalmol 1998; 116: 443–447. (10.1001/archopht.116.4.443) / Arch Ophthalmol by DS Greenfield (1998)
  62. Kupin TH et al. Adjunctive mitomycin C in primary trabeculectomy in phakic eyes. Am J Ophthalmol 1995; 119: 30–39. (10.1016/S0002-9394(14)73810-3) / Am J Ophthalmol by Kupin TH (1995)
  63. Crowston JG et al. Antimetabolites-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci 1998; 39: 449–454. / Invest Ophthalmol Vis Sci by JG Crowston (1998)
Dates
Type When
Created 22 years, 7 months ago (Jan. 13, 2003, 10:49 a.m.)
Deposited 3 years, 4 months ago (March 29, 2022, 10:05 p.m.)
Indexed 3 weeks, 2 days ago (Aug. 6, 2025, 8:39 a.m.)
Issued 22 years, 7 months ago (Jan. 1, 2003)
Published 22 years, 7 months ago (Jan. 1, 2003)
Published Online 22 years, 7 months ago (Jan. 13, 2003)
Published Print 22 years, 7 months ago (Jan. 1, 2003)
Funders 0

None

@article{Cordeiro_2003, title={Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome}, volume={10}, ISSN={1476-5462}, url={http://dx.doi.org/10.1038/sj.gt.3301865}, DOI={10.1038/sj.gt.3301865}, number={1}, journal={Gene Therapy}, publisher={Springer Science and Business Media LLC}, author={Cordeiro, M F and Mead, A and Ali, R R and Alexander, R A and Murray, S and Chen, C and York-Defalco, C and Dean, N M and Schultz, G S and Khaw, P T}, year={2003}, month=jan, pages={59–71} }